Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

statnews.com

STAT

Get the latest updates from STAT directly as they happen.

Follow now 208 followers

Latest posts

Last updated about 7 hours ago

STAT+: Academic groups finalize counterproposal to Trump’s research overhead cuts

about 7 hours ago

A coalition of academic organizations has finalized a proposed alternative to the...

NIH grant cuts, FDA transparency questions, and biotech M&A

about 12 hours ago

On this week’s episode of “The Readout LOUD”: a closer look at...

FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility

about 14 hours ago

Moderna’s Covid-19 vaccine for children has been given full Food and Drug...

STAT+: FDA won’t pay 2024 bonuses to workers who are getting laid off

about 17 hours ago

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about...

STAT+: FDA publishes rejection letters sent to drugmakers, with a big caveat

about 18 hours ago

The Food and Drug Administration on Thursday published more than 200 letters...

STAT+: Brawl over Eylea gets biosimilar industry’s attention

about 18 hours ago

Hello! Today, we talk about a cool experimental enzyme therapy, observe more...

STAT+: Eyes on Soleno’s Prader-Willi drug launch

about 21 hours ago

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter...

STAT+: Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million

about 21 hours ago

With investors and drugmakers increasingly eyeing the kidney disease space, a new...

Opinion: STAT+: How to evaluate GLP-1s and Medicare costs? Here’s one idea

about 23 hours ago

Today, more than 40% of adults over 60 are considered obese, fueling...

MAHA’s European food envy is full of contradictions

about 23 hours ago

The idea of making the U.S. more like Europe is anathema to...

STAT+: How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition

about 23 hours ago

A court battle between two of the nation’s largest biotechs — Regeneron...